Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: A practical review

Nosha Farhadfar, Sonia Cerquozzi, Mrinal Patnaik, Ayalew Tefferi

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in shortened survival and leukemic transformation. It is a disease predominantly of the elderly, and currently available therapies only offer symptom control without curative benefit or ability to alter disease progression. Allogeneic hematopoietic stem-cell transplant (HSCT) is the only potentially curative intervention; however, this is only feasible in younger and medically fit patients and selectively offered to those with high-risk disease. Despite ongoing advancements, HSCT is associated with substantial morbidity and mortality, and the determination of which patients with myelofibrosis are ideal candidates and the selection of the opportune moment to proceed with transplantation remains challenging. This review summarizes our current recommendations for the role of and indications for HSCT in myelofibrosis.

Original languageEnglish (US)
Pages (from-to)611-621
Number of pages11
JournalJournal of oncology practice
Issue number7
StatePublished - Jul 2016

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy


Dive into the research topics of 'Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: A practical review'. Together they form a unique fingerprint.

Cite this